Nachrichten zur Vertex Pharmaceuticals Inc. Aktie

Is Vertex Pharmaceuticals Stock a Buy Now?

The company just released its latest earnings report, and growth investors may be a little disappointed.…

Is Vertex Pharmaceuticals Stock a Buy Now? @themotleyfool #stocks $VRTX

The company just released its latest earnings report, and growth investors may be a little disappointed.…

Could Vertex Pharmaceuticals Reach $500 in 2024?

Vertex shares have several catalysts on the horizon...…

Could Vertex Pharmaceuticals Reach $500 in 2024? @themotleyfool #stocks $VRTX

Vertex shares have several catalysts on the horizon...…

Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Heres How You Can Invest

Its foray into developing analgesics seems to be going swimmingly.…

Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Heres How You Can Invest @themotleyfool #stocks $VRTX

Its foray into developing analgesics seems to be going swimmingly.…

Futures Dip; Palantir Soars On Surging AI Demand

Other key earnings movers include Eli Lilly, Spotify and Vertex Pharmaceuticals.…

Vertex Pharmaceuticals: Gute Q4-Zahlen - Das nächste Mukoviszidose-Mittel steht in den Startlöchern - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript

VRTX earnings call for the period ending December 31, 2023.…

Vertex Pharmaceuticals Incorporated 2023 Q4 - Results - Earnings Call Presentation

…

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?

…

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?

Vertex shares recently reached an all-time high.…

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy? @themotleyfool #stocks $VRTX

Vertex shares recently reached an all-time high.…

These companies have earnings momentum heading into their reports next week

Analysts have grown increasingly bullish on Vertex Pharmaceuticals and Uber, among other companies that will issue their latest financials next…

Vertex Pharmaceuticals: Kursziel um 50 USD angepasst

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Oppenheimer belassen die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol:…

Vertex Pharmaceuticals abgestuft

New York (www.aktiencheck.de) - Rating-Update: Das Investmenthaus Maxim Group streicht seine Kaufempfehlung für die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003,…

Vertex Pharmaceuticals: Kursziel erhöht

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Die Analysten von Truist belassen die Aktie des amerikanischen Biotech-Riesen Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

Vertex Pharmaceuticals: Der Teufel steckt im Detail - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Solvias führt Freigabetests für die weltweit erste CRISPR-basierte Gen-Editierungstherapie durch

Solvias: Kaiseraugst, Schweiz (ots/PRNewswire) - Globaler Anbieter unterzeichnet langfristiges Abkommen mit Vertex Pharmaceuticals für CASGEVY™ Solvias, ein globaler Anbieter von…

Pro Research: Wall Street delves into Vertex Pharmaceuticals By Investing.com

Pro Research: Wall Street delves into Vertex Pharmaceuticals…

If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today @themotleyfool #stocks $VRTX $CRSP

Has investing in Vertex been a better option than just putting your money in the S&P 500?…

If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today

Has investing in Vertex been a better option than just putting your money in the S&P 500?…

Vertex Pharmaceuticals: RBC Capital erhöht Kursziel vor Studiendaten - Aktienanalyse

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets: RBC Capital Markets stuft die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003,…

Vertex Pharmaceuticals: Kursziel angehoben

Minneapolis (www.aktiencheck.de) - Rating-Update: Die Analysten von Piper Sandler bewerten die Aktie des US-Biotechkonzerns Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807,…

CRISPR Therapeutics und Vertex: Der nächste Durchbruch

Vertex Pharmaceuticals und CRISPR Therapeutics haben Grund zum Feiern: Ihre gemeinsam entwickelte CRISPR-basierte Gentherapie hat eine weitere Zulassung erhalten. Die…

US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder

The U.S. health regulator approved Vertex Pharmaceuticals and CRISPR Therapeutics gene therapy to treat a blood disorder requiring regular blood…

CRISPR/Vertex gene editing drug cleared for beta-thalassemia

ipopba Vertex Pharmaceuticals (NASDAQ:VRTX) announced Tuesday that the U.S. FDA approved its groundbreaking gene editing therapy, Casgevy, developed with CRISPR…

Vertex Pharmaceuticals Is One Of Our Favorite Biotech Ideas

…

2 Low-Priced Gene Therapy Stocks to Speculate On

Stocks Analysis by MarketBeat.com (Jea Yu) covering: Novartis AG, Vertex Pharmaceuticals Inc, Biogen Inc, Pfizer Inc. Read MarketBeat.com (Jea Yu)s…

Vertex Pharmaceuticals: A Full Pipeline

…

Is Vertex Pharmaceuticals Stock a Buy Now?

The biotechs prospects keep improving.…

Amgen: Neues Allzeithoch! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Amgen-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

VIRICA Index gibt Vollgas: Regeneron, Amgen und Vertex auf Rekordhoch

Die Aktien der amerikanischen Biotech-Riesen Vertex Pharmaceuticals, Amgen und Regeneron haben einen bärenstarken Start ins Börsenjahr 2024 hingelegt. Alle drei…

3 Reasons to Buy Vertex Pharmaceuticals Stock Like Theres No Tomorrow

With a new medicine on the market and plenty of money, Vertex is in great shape.…

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals

Editas isnt out of the woods yet, but its better off than before.…

Diese 2 Aktien sollte man im Jahr 2024 auf der Watchlist haben

Das Börsenjahr 2023 neigt sich langsam dem Ende zu. Investoren, die Aktien von CrowdStrike (WKN: A2PK2R) und Vertex Pharmaceuticals (WKN:…

Is Vertex Pharmaceuticals Sitting on a Gold Mine?

Vertex shares have climbed about 40% this year.…

Is Vertex Pharmaceuticals Sitting on a Gold Mine? @themotleyfool #stocks $VRTX $CRSP

Vertex shares have climbed about 40% this year.…

Charles Rivers (CRL) Memphis Site Achieves Crucial Approval

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.…

5 Big Drug Stocks That May Continue to Outperform in 2024

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year.…

Vertex Pharmaceuticals: Shares are Under Heavy Accumulation

…

AKTIONÄR-Depotwerte CRISPR Therapeutics und Vertex: Gen-Schere-Therapie bald auch in der EU

Vor Kurzem bereits hat die US-Gesundheitsbehörde FDA der ersten CRISPR/Cas9-basierten Therapie Casgevy (Exa-cel) vom Forschungsduo CRISPR Therapeutics und Vertex Pharmaceuticals…

AKTIONÄR-Depotwerte CRISPR Therapeutics und Vertex: Gen-Schere-Therapie bald auch in der EU

Vor Kurzem bereits hat die US-Gesundheitsbehörde FDA der ersten CRISPR/Cas9-basierten Therapie Casgevy (Exa-cel) vom Forschungsduo CRISPR Therapeutics und Vertex Pharmaceuticals…

Vertex Pharmaceuticals: Große Marktchancen - Aktienanalyse

London (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Barclays: Die Analysten von Barclays erhöhen in einer aktuellen Aktienanalyse ihr Kursziel für die Aktie…

Vertex Pharmaceuticals: Kursziel verbessert

San Francisco (www.aktiencheck.de) - Rating-Update: Die Analysten von Wells Fargo Advisors bewerten die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN…

Vertex Pharmaceuticals: Kursziel angehoben

London (www.aktiencheck.de) - Rating-Update: Gena Wang, Analystin von Barclays, stuft die Aktie des US-Biotechkonzerns Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN 882807,…

Vertex Pharmaceuticals: Eine erhöhte Erfolgswahrscheinlichkeit von VX-548 - Aktienanalyse

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, erhöht das Kursziel für…

Vertex Pharmaceuticals: Neue Rekordstände! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Vertex Pharmaceuticals Inc.…

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the…

Vertiass $100M deal to license Editas IP sets a precedent for gene-editing therapy developers in the US

Vertex Pharmaceuticals (NASDAQ:VRTX) shares surged more than 13% to a record higher Wednesday after the company announced an agreement to…